Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS Author FAQs
    • COVID-19 submission information
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS Author FAQs
    • COVID-19 submission information
  • Alerts
  • Subscriptions

Impact of COVID-19 on COPD and asthma admissions, and the pandemic from a patient's perspective

Dominic L. Sykes, Shoaib Faruqi, Luke Holdsworth, Michael G. Crooks
ERJ Open Research 2021 7: 00822-2020; DOI: 10.1183/23120541.00822-2020
Dominic L. Sykes
Respiratory Research Group, Hull University Teaching Hospitals, Hull, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dominic L. Sykes
  • For correspondence: Dominic.sykes@hey.nhs.uk
Shoaib Faruqi
Respiratory Research Group, Hull University Teaching Hospitals, Hull, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shoaib Faruqi
Luke Holdsworth
Respiratory Research Group, Hull University Teaching Hospitals, Hull, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael G. Crooks
Respiratory Research Group, Hull University Teaching Hospitals, Hull, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

There has been a significant reduction in all-cause and exacerbation-related #asthma and #COPD admissions during the #COVID19 pandemic. Patients also report a subjective decline in disease control and describe a negative impact on their mental health. https://bit.ly/2Kv0O0H

To the Editor:

The coronavirus disease 2019 (COVID-19) pandemic has led to an overall reduction in hospital admissions in the United Kingdom (UK) with national data showing a decline in emergency admissions for respiratory illness [1, 2].

Patients with asthma and COPD are considered at increased risk of dying from COVID-19 and were therefore subject to UK Government shielding advice. While this may have protected against respiratory viruses; adverse effects, including reduced physical activity, social isolation, and increasing anxiety have been recognised consequences [3]. Airways disease management is multidisciplinary and there may also be pervasive deleterious effects due to suspension of clinical services including outpatient clinics, smoking cessation support, and pulmonary rehabilitation (PR) [4]. A recent national survey found that up to 23% of patients with lung conditions have experienced worsening symptoms during the pandemic [5].

We examine admissions with exacerbations of asthma and COPD to Hull University Teaching Hospitals NHS Trust (HUTH) during the first wave of the COVID-19 pandemic and compare them to previous years. We then explore the patients’ perspective of the pandemic and how it affected their physical and mental health.

All admissions to HUTH (an NHS Trust with two large hospital sites) with a diagnosis of asthma or COPD between March 23 and June 1, 2020 were identified from hospital electronic records. Data were collected using identical search criteria for aligned dates in 2018 and 2019. Electronic health records were reviewed for all identified admissions to ascertain those with a primary diagnosis of asthma or COPD exacerbation. Data collected included, demographics, diagnosis, level of care received, length of stay and acute treatment.

Patients with COPD under active clinical follow-up by the local integrated COPD service were contacted and provided verbal consent to undertake a structured interview consisting of 20 questions relating to their experience of their COPD and its treatment during the COVID-19 pandemic. Interview questions were related to subjective disease control, mental health impacts, patient physical activity and medication use. Local data from the UK Severe Asthma Registry (UKSAR) study, examining the experience of severe asthma patients during the pandemic, were also collated [6].

All data were analysed using IBM SPSS Statistics 26 (IBM Corp., Armonk, NY, USA), differences in proportions were analysed using Chi-squared testing, comparisons of means were analysed using ANOVA, and all results are presented descriptively.

Data are presented in table 1.

View this table:
  • View inline
  • View popup
TABLE 1

The number of admissions and admission-related information from March 23–June 1 in 2018, 2019, and 2020

We identified 4665 all-cause admissions for patients with a diagnosis of asthma or COPD during the studied period, of which 883 were for exacerbations. The mean number of all-cause admissions per week in our study period fell significantly from 173 and 179.7 in 2018 and 2019 respectively to 113.8 per week in 2020 (p<0.001). Mean number of airways disease exacerbations per week also reduced from 36 and 36.6 per week in 2018 and 2019 respectively to 15.7 per week in 2020 (p<0.001).

No difference was observed in the proportion of patients hospitalised with exacerbations requiring admission to critical care. However, there was a significant reduction in the proportion of patients admitted to the respiratory high-dependency unit (HDU) in 2020 (p=0.03).

Oral corticosteroids were prescribed in a lower proportion of patients hospitalised with an exacerbation in 2020 compared with earlier years (80.1% in 2020 versus 88.1% in 2019 and 88.4% in 2018, p=0.004). No difference was observed in inpatient mortality.

Fifty patients with COPD were interviewed. One patient had recovered from COVID-19. Eight (16%) had been hospitalised with exacerbations during the study period. Overall, 48% (n=24) reported that the pandemic had a negative impact on their mental health.

Of the patients interviewed, 32% (n=16) reported worsening of their COPD control. Reduction in daily exercise was reported in 46% (n=23), and 57% (n=13) of these patients reported their COPD control as worse. Increased use of ‘reliever’ inhalers was reported in 48% (n=24), and 22% (n=11) of patients disclosed that at least on one occasion over the pandemic they felt as though they were exacerbating and did not seek medical help.

Eighty-two patients with severe asthma were interviewed with the UKSAR COVID questionnaire, of which 34.1% (n=28) reported their disease control to be worse. Overall, 18.3% (n=15) of patients reported the pandemic as having a negative effect on their mental health. Only one patient interviewed had a hospital admission for an asthma exacerbation in 2020.

We confirm a significant reduction in all-cause and exacerbation-related hospitalisations for patients with asthma and COPD during the first wave of the COVID-19 pandemic. This is in keeping with national emergency admission data [2] and similar data from other countries [7, 8].

There are several possible explanations for the observed reduction in hospitalisation with airways disease exacerbations. Patient's response to respiratory symptoms may have been altered by the COVID-19 pandemic, making them less likely to seek care. Indeed, a national survey conducted by the British Lung Foundation reported that 70% of patients did not feel safe seeking treatment due to fear of COVID-19 [5]. This may have impacted all-cause admissions, but we feel it is unlikely that this adequately explains the reduction in exacerbations given that no change was observed in the acuity of the admitted patients. Conversely, we observed a reduction in the proportion of hospitalised patients with asthma and COPD requiring HDU-level care and there was no change in intensive care unit admission or inpatient mortality. This suggests that those being hospitalised with exacerbations were not more unwell than during previous years.

We demonstrated a significant reduction in inpatient steroid prescriptions for patients presenting with asthma and COPD exacerbations in 2020 when compared to 2019 and 2018 combined (80.1% versus 88.3%, p=0.004). There are many possible explanations for this. The studied period predates the preliminary reports of dexamethasone utility in COVID-19 from the RECOVERY trial [9] and concern about potential adverse effects of steroids in COVID-19 were prevalent, potentially influencing prescribing practice. Our data do not allow us to draw firm conclusions about the reason for the observed reduction in steroid prescribing and therefore should be considered hypothesis-generating.

In our study, 32% of patients with COPD and 34.1% of patients with asthma reported a subjective decline in their condition. Many reported exercising less and using their reliever inhaler more often. Deconditioning is a common cause of increased symptom burden in COPD and is likely a contributing factor in our cohort. Similar results were observed in a recent study by McAuley et al. [3] with an overall reduction in physical activity in patients with COPD leading to general deconditioning. A sedentary lifestyle is associated with worse outcomes including mortality in patients with COPD and it is therefore essential that this trend is reversed as we recover from the COVID-19 pandemic. PR is known to improve quality of life and exercise capacity in COPD and should be a key priority for health systems [10, 11]. Our data do not identify the reason for the apparent discordance between perceived disease control and reduction in exacerbations requiring hospital admission among patients with severe asthma. This relationship is worthy of further study.

The impact of the COVID-19 pandemic and its sequelae (i.e. social distancing, shielding, and national “lockdowns”) on mental health was evident in our study [12]. This was particularly apparent in our COPD cohort with almost half (48%) patients reporting a negative impact of the pandemic on their mental health. This contrasts with 18.3% of interviewed patients with severe asthma. The link between depression, anxiety and COPD is well reported, with evidence to suggest that more severe COPD increases the likelihood of psychological morbidity [13].

The limitations of our study include it being single-centre and the relatively small sample of patients interviewed. The perspectives of patients with asthma were obtained from a cohort participating in the UKSAR study and therefore only patients with severe asthma were included, limiting generalisability to a broader asthma population. We were unable to account for confounding factors in the management strategies for patients with airways disease, so cannot draw definitive conclusions regarding the observed reduction in steroid prescribing. However, we report robust, in-depth analysis, of admission data during the pandemic compared with date-matched periods in previous years and provide insights into patients’ experiences.

We report a significant reduction in all-cause and exacerbation-related asthma and COPD admissions during the first wave of the COVID-19 pandemic in the UK. Despite a reduction in exacerbation-related admissions, patients report a subjective decline in their disease control and describe a negative impact on their mental health, which is most profound among patients with COPD.

Footnotes

  • Approval for this study was granted from the Hull University Teaching Hospitals Trust governance committee.

  • Conflict of interest: D.L. Sykes has nothing to disclose.

  • Conflict of interest: S. Faruqi has nothing to disclose.

  • Conflict of interest: L. Holdsworth has nothing to disclose.

  • Conflict of interest: M.G. Crooks has nothing to disclose.

  • Received November 4, 2020.
  • Accepted November 18, 2020.
  • Copyright ©ERS 2021
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. NHS. Monthly Hospital Activity
    . www.england.nhs.uk/statistics/statistical-work-areas/hospital-activity/monthly-hospital-activity/. Date last accessed: September 21, 2020. Date last updated: July 9, 2020.
  2. ↵
    1. UK Government. Emergency department: weekly bulletins for 2020
    . www.gov.uk/government/publications/emergency-department-weekly-bulletins-for-2020. Date last accessed: September 23, 2020.
  3. ↵
    1. McAuley H,
    2. Hadley K,
    3. Elneima O, et al.
    COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD. ERJ Open Res 2021; 7: 00718-2020. doi:10.1183/23120541.00718-2020
  4. ↵
    1. Deslée G,
    2. Zysman M,
    3. Burgel PR, et al.
    Chronic obstructive pulmonary disease and the COVID-19 pandemic: reciprocal challenges. Respir Med Res 2020; 78: 100764. doi:10.1016/j.resmer.2020.100764
    OpenUrl
  5. ↵
    1. British Lung Federation. Over a third of people with lung conditions felt pressure to avoid or delay seeking treatment during lockdown
    . www.blf.org.uk/taskforce/press-release/over-a-third-of-people-with-lung-conditions-felt-pressure-to-avoid-or-delay-seeking-treatment. Date last accessed: September 28, 2020.
  6. ↵
    1. Smith SJ,
    2. Busby J,
    3. Heaney LG, et al.
    The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown? ERJ Open Res 2021; 7: 00768-2020. Doi:10.1183/23120541.00768-2020
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Chan KP,
    2. Ma TF,
    3. Kwok WC, et al.
    Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic. Lancet Respir Med 2020; 171: 106085. doi:10.1016/j.rmed.2020.106085
    OpenUrl
  8. ↵
    1. Berghaus TM,
    2. Karschnia P,
    3. Haberl S, et al.
    Disproportionate decline in admissions for exacerbated COPD during the COVID-19 pandemic. Respir Med 2020; in press [https://doi.org/10.1016/j.rmed.2020.106120]. doi:10.1016/j.rmed.2020.106120
  9. ↵
    1. Horby P,
    2. Lim WS,
    3. Emberson JR, et al.
    Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med 2020; in press [https://doi.org/10.1056/NEJMoa2021436]. doi:10.1056/NEJMoa2021436
  10. ↵
    1. Furlanetto KC,
    2. Donária L,
    3. Schneider LP, et al.
    Sedentary behavior is an independent predictor of mortality in subjects with COPD. Respir Care 2017; 62: 579–587. doi:10.4187/respcare.05306
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Cote CG,
    2. Celli BR
    . Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005; 26: 630–636. doi:10.1183/09031936.05.00045505
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Pierce M,
    2. Hope H,
    3. Ford T, et al.
    Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. Lancet Psychiatry 2020; 7: 883–892. doi:10.1016/S2215-0366(20)30308-4
    OpenUrl
  13. ↵
    1. Yohannes AM,
    2. Alexopoulos GS
    . Depression and anxiety in patients with COPD. Eur Respir Rev 2014; 23: 345–349. doi:10.1183/09059180.00007813
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Vol 7 Issue 1 Table of Contents
ERJ Open Research: 7 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of COVID-19 on COPD and asthma admissions, and the pandemic from a patient's perspective
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Impact of COVID-19 on COPD and asthma admissions, and the pandemic from a patient's perspective
Dominic L. Sykes, Shoaib Faruqi, Luke Holdsworth, Michael G. Crooks
ERJ Open Research Jan 2021, 7 (1) 00822-2020; DOI: 10.1183/23120541.00822-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of COVID-19 on COPD and asthma admissions, and the pandemic from a patient's perspective
Dominic L. Sykes, Shoaib Faruqi, Luke Holdsworth, Michael G. Crooks
ERJ Open Research Jan 2021, 7 (1) 00822-2020; DOI: 10.1183/23120541.00822-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • COPD and smoking
  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Duration of RA and the risk of developing ILD
  • Prevalence of stress urinary incontinence in chronic cough
  • What is important for people with NTM?
Show more Original research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2021 by the European Respiratory Society